Experience in the Treatment of Male Prolactinomas: A Single-Center, 10-Year Retrospective Study
Male prolactinoma has a low biochemical remission rate when treated alone, but multitherapy can improve it even more. Surgery may also be considered for male prolactinoma with a micro, and noninvasive tumor after a thorough evaluation.
Authors
- Xiaoan Ke (ORCID: https://orcid.org/0000-0002-4182-2890)
- Xiaoxue Chen (ORCID: https://orcid.org/0000-0002-2077-6020)
- Lian Duan (ORCID: https://orcid.org/0000-0002-4213-474X)
- Huijuan Zhu (ORCID: https://orcid.org/0000-0001-5172-6870)
- Fengying Gong (ORCID: https://orcid.org/0000-0002-3832-5674)
- Hongbo Yang (ORCID: https://orcid.org/0000-0002-5193-8838)
- Hui Pan
- Kan Deng (ORCID: https://orcid.org/0000-0001-9571-3705)
- Linjie Wang (ORCID: https://orcid.org/0000-0001-9672-7703)
- Yong Yao (ORCID: https://orcid.org/0000-0001-6982-8832)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Neuroendocrinology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1159/000541495
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Peking Union Medical College Hospital
- Peking Union Medical College